tiprankstipranks
Trending News
More News >
Medical Ikkou Group Co., Ltd. (JP:3353)
:3353
Japanese Market
Advertisement

Medical Ikkou Group Co., Ltd. (3353) AI Stock Analysis

Compare
1 Followers

Top Page

JP:3353

Medical Ikkou Group Co., Ltd.

(3353)

Select Model
Select Model
Select Model
Outperform 82 (OpenAI - 4o)
Rating:82Outperform
Price Target:
¥4,114.00
▲(33.57% Upside)
The stock score is strong, primarily driven by strong financial performance with robust revenue growth and operational efficiency. Technical analysis supports a bullish trend, while reasonable valuation adds to its attractiveness. However, cash flow challenges and a modest dividend yield are potential concerns.

Medical Ikkou Group Co., Ltd. (3353) vs. iShares MSCI Japan ETF (EWJ)

Medical Ikkou Group Co., Ltd. Business Overview & Revenue Model

Company DescriptionMedical Ikkou Group Co., Ltd. is a Japanese company operating primarily in the healthcare sector. The company is involved in the retail and wholesale of pharmaceuticals and medical supplies. It serves a broad customer base, including hospitals, clinics, and pharmacies, providing them with essential medications and healthcare products. Additionally, Medical Ikkou Group may engage in the management and operation of pharmacies and drugstores, contributing to its comprehensive approach to healthcare service delivery.
How the Company Makes MoneyMedical Ikkou Group Co., Ltd. generates revenue through multiple streams. Primarily, the company earns income by selling pharmaceuticals and medical supplies to various clients such as hospitals, clinics, and individual customers through its retail and wholesale channels. The operation and management of pharmacies and drugstores also contribute significantly to its revenue, allowing the company to capture retail margins from direct consumer sales. Furthermore, the company might engage in distribution agreements or partnerships with pharmaceutical manufacturers, enabling it to expand its product offerings and enhance its supply chain efficiency. These partnerships can provide additional revenue opportunities through exclusive distribution rights or volume-based incentives.

Medical Ikkou Group Co., Ltd. Financial Statement Overview

Summary
Medical Ikkou Group Co., Ltd. shows strong revenue growth and operational efficiency with an improved gross profit margin. However, challenges are present in net profitability and cash flow management, despite a stable balance sheet indicating healthy equity and manageable debt levels.
Income Statement
88
Very Positive
Medical Ikkou Group Co., Ltd. has shown strong revenue growth with a 21.3% increase from 2024 to 2025. The gross profit margin has improved to 11.6% in 2025 from 11.4% in 2024, indicating better cost management. The EBIT margin also improved to 3.5% in 2025 from 3.9% in 2024, showcasing operational efficiency. However, the net profit margin remained stable at around 2.3%, suggesting room for improvement in net profitability.
Balance Sheet
81
Very Positive
The company maintains a healthy equity ratio of 41.2% in 2025, reflecting strong solvency. The debt-to-equity ratio decreased to 0.71 in 2025 from 0.72 in 2024, showing effective debt management. ROE was stable at 8.0% in 2025, indicating consistent return on shareholders' equity. However, the total debt level remains significant, which could pose a risk if not managed properly.
Cash Flow
75
Positive
Operating cash flow decreased significantly to ¥1.2 billion in 2025 from ¥4.3 billion in 2024, negatively impacting free cash flow, which dropped by 94.9%. The free cash flow to net income ratio declined, signaling potential cash flow issues relative to earnings. However, the company generated positive free cash flow, indicating some level of operational efficiency.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue48.39B48.39B39.90B33.90B33.60B31.60B
Gross Profit5.67B5.61B4.55B3.18B3.61B3.20B
EBITDA2.66B2.73B2.50B2.21B2.41B2.33B
Net Income1.13B1.13B1.04B759.60M852.33M834.99M
Balance Sheet
Total Assets34.23B34.23B31.66B27.51B29.09B28.55B
Cash, Cash Equivalents and Short-Term Investments6.77B6.77B7.70B6.44B7.99B7.00B
Total Debt10.02B10.02B9.58B9.12B11.31B11.85B
Total Liabilities19.52B19.52B17.82B14.90B17.17B18.07B
Stockholders Equity14.10B14.10B13.24B12.05B11.38B10.48B
Cash Flow
Free Cash Flow0.00201.34M3.95B960.14M798.00M1.33B
Operating Cash Flow0.001.20B4.28B1.31B1.14B1.82B
Investing Cash Flow0.00-1.13B-3.22B-477.52M-215.52M-1.18B
Financing Cash Flow0.00-1.03B277.76M-2.37B64.74M590.88M

Medical Ikkou Group Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price3080.00
Price Trends
50DMA
3099.62
Negative
100DMA
2811.91
Positive
200DMA
2466.01
Positive
Market Momentum
MACD
9.90
Negative
RSI
48.89
Neutral
STOCH
44.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3353, the sentiment is Neutral. The current price of 3080 is above the 20-day moving average (MA) of 3074.45, below the 50-day MA of 3099.62, and above the 200-day MA of 2466.01, indicating a neutral trend. The MACD of 9.90 indicates Negative momentum. The RSI at 48.89 is Neutral, neither overbought nor oversold. The STOCH value of 44.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3353.

Medical Ikkou Group Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
¥10.64B10.243.22%19.52%-9.23%
79
Outperform
¥6.67B11.0720.37%2.40%4.11%115.34%
76
Outperform
¥10.19B12.4016.88%3.10%16.82%52.74%
74
Outperform
¥8.87B14.232.64%1.96%0.55%95.43%
71
Outperform
¥9.69B5.558.33%4.74%-2.82%18.67%
66
Neutral
¥8.69B8.204.06%4.02%5.00%25.91%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3353
Medical Ikkou Group Co., Ltd.
3,080.00
815.90
36.04%
JP:6554
SUS Co., Ltd.
1,128.00
450.11
66.40%
JP:7066
Peers Co. Ltd.
666.00
-112.52
-14.45%
JP:7490
Nissin Shoji Co., Ltd.
1,328.00
463.08
53.54%
JP:7670
O-WELL CORPORATION
949.00
116.20
13.95%
JP:7795
Kyoritsu Co., Ltd.
199.00
51.60
35.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 18, 2025